叶酸偶联表阿霉素脂质体的构建及其增强侵袭性乳腺癌细胞摄取和核定位效应的研究

doi:10.5246/jcps.2018.04.024

中国药学(英文版) ›› 2018, Vol. 27 ›› Issue (4): 229-240.DOI: 10.5246/jcps.2018.04.024

叶酸偶联表阿霉素脂质体的构建及其增强侵袭性乳腺癌细胞摄取和核定位效应的研究

卜英子, 沐黎敏, 刘磊, 吕万良^*

北京大学医学部药学院分子药剂学与新释药系统北京市重点实验室; 天然药物及仿生药物国家重点实验室, 北京 100191

收稿日期:2018-01-22 修回日期:2018-02-22 出版日期:2018-04-30 发布日期:2018-03-05
通讯作者: Tel./Fax: +86-010-82802683, E-mail: luwl@bjmu.edu.cn
基金资助:
The National Natural Science Foundation of China (Grant No. 81373343 and 81673367).

Construction of folate-conjugated epirubicin liposomes for enhancing the cellular uptake and the co-localization with nuclei of invasive breast cancer cells

Yingzi Bu, Limin Mu, Lei Liu, Wanliang Lu^*

Beijing Key Laboratory of Molecular Pharmaceutics and New Drug System; State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China

Received:2018-01-22 Revised:2018-02-22 Online:2018-04-30 Published:2018-03-05
Contact: Tel./Fax: +86-010-82802683, E-mail: luwl@bjmu.edu.cn
Supported by:
The National Natural Science Foundation of China (Grant No. 81373343 and 81673367).

摘要/Abstract

摘要：

侵袭性乳腺癌对蒽环类药物表现出较强的抗药性,其原因与药物在癌细胞摄取减少、难以定位到细胞核相关。本研究旨在构建一种叶酸偶联表阿霉素脂质体,将新合成的叶酸-脂质衍生物修饰到脂质体上,以增强侵袭性乳腺癌细胞的药物摄取和细胞核共定位,从而达到清除癌细胞的效果。研究以侵袭性乳腺癌细胞MDA-MB-435S细胞为模型展开。本研究合成了新型叶酸-PEG₂₀₀₀-DSPE共聚物,并构建了叶酸偶联表阿霉素脂质体,载药脂质体的平均粒径约为100 nm;体外试验表明,同对照组相比,叶酸偶联表阿霉素脂质体表现出最强的癌细胞摄取效应和癌细胞核定位效应;并且,构建的载药脂质体表现最强的杀伤侵袭性乳腺癌细胞效应、抑制侵袭性乳腺癌细胞损伤修复效应和对体外乳腺癌肿瘤球最强的穿透效应。因此,构建的叶酸偶联表阿霉素脂质体可通过增加侵袭性乳腺癌细胞摄取及细胞核共定位效应,达到杀伤侵袭性乳腺癌细胞的效果。通过后续开发,叶酸偶联表阿霉素脂质体可望成为一种治疗侵袭性乳腺癌的新型制剂,该研究也为侵袭性乳腺癌治疗提供了潜在的新策略。

关键词: 叶酸偶联脂质体, 表阿霉素, 细胞摄取, 细胞核共定位, 侵袭性乳腺癌

Abstract:

Drug resistance of anthracycline in the invasive cancer is associated with the lowered cellular drug uptake and diminished co-localization of drug with nuclei. In the present study, we aimed to construct the folate-conjugated epirubicin liposomes by incorporating a synthesized folate-lipid derivative; and to assess the effects on cellular drug uptake, co-localization of drug with nuclei and efficacy in treatment of invasive breast cancer cells. The studies were performed on invasive human breast cancer cells. The folate-PEG₂₀₀₀-DSPE conjugate was synthesized, and the constructed folate-conjugated epirubicin liposomes were approximately 100 nm in size. The in vitro studies demonstrated that the folate-conjugated epirubicin liposomes had the strongest cellular drug uptake and co-localization with nuclei of the invasive breast cancer cells. Besides, the liposomes displayed the most significant efficacy in killing the invasive cancer cells, in preventing their invasive potential, and in penetrating ability into breast cancer spheroid as well. In conclusion, the constructed folate-conjugated epirubicin liposomes were able to enhance the efficacy in treatment of invasive breast cancer by improving the cellular drug uptake and increasing the co-localization with nuclei, hence offering a new strategy for potentially eradicating the invasive breast cancer cells.

Key words: Folate conjugated liposomes, Epirubicin, Cellular uptake, Co-localization with nuclei, Invasive breast cancer

中图分类号:

R943

Supporting:

卜英子, 沐黎敏, 刘磊, 吕万良. 叶酸偶联表阿霉素脂质体的构建及其增强侵袭性乳腺癌细胞摄取和核定位效应的研究[J]. 中国药学(英文版), 2018, 27(4): 229-240.

Yingzi Bu, Limin Mu, Lei Liu, Wanliang Lu. Construction of folate-conjugated epirubicin liposomes for enhancing the cellular uptake and the co-localization with nuclei of invasive breast cancer cells[J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(4): 229-240.

参考文献

[1] Youlden, D.; Cramb, S.; Dunn, N.; Muller, J.; Pyke, C.; Baade, P.D. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol. 2012, 36, 237-248.

[2] Porter, H.; Perry, A.; Kingsley, C.; Tran, N.L.; Keegan, A.D. IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors. Cancer Lett. 2015, 338, 239-248.

[3] Mu, L.M.; Ju, R.J.; Liu, R.; Bu, Y.Z.; Zhang, J.Y.; Li, X.Q.; Zeng, F.; Lu, W.L. Dual-functional drug liposomes in treatment of resistant cancers. Adv. Drug Deliv. Rev. 2017, 115, 46-56.

[4] Conte, P.F.; Gennari, A.; Landucci, E.; Orlandini, C. Role of epirubicin in advanced breast cancer. Clin. Breast. Cancer. 2000, 1, S46-51.

[5] Cowell, I.G.; Austin, C.A. Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents. Int. J. Environ. Res. Public. Health. 2012, 9, 2075-2091.

[6] Coukell, A.J.; Faulds, D. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer. Drugs. 1997, 53, 453-482.

[7] Alberg, A.J.; Selhub, J.; Shah, K.V.; Viscidi, R.P.; Comstock, G.W.; Helzlsouer, K.J. The risk of cervical cancer in relation to serum concentrations of folate, vitamin B12, and homocysteine. Cancer Epidemiol. Biomarkers Prev. 2000, 9, 761-764.

[8] Li, Y.; Huang, T.; Zheng, Y.; Muka, T.; Troup, J.; Hu, F.B. Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials. J. Am. Heart Assoc. 2016, 15, 5.

[9] Christen, W.G.; Glynn, R.J.; Chew, E.Y.; Albert, C.M.; Manson, J.E. Folic acid, pyridoxine, and cyanocobalamin combination treatment and age-related macular degeneration in women: the Women's Antioxidant and Folic Acid Cardiovascular Study. Arch. Intern. Med. 2009, 169, 335-341.

[10] Leamon, C.; Reddy, J.A. Folate-targeted chemotherapy. Adv. Drug Deliv. Rev. 2004, 56, 1127-1141.

[11] Giovannucci, E. Epidemiologic studies of folate and colorectal neoplasia: a review. J. Nutr. 2002, 132, 2350S-2355S.

[12] Ross, J.F.; Chaudhuri, P.K.; Ratnam, M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer. 1994, 73, 2432-2443.

[13] Garin-Chesa, P.; Campbell, I.; Saigo, P.E.; Lewis, J.L.; Old, L.J.; Rettig, W.J. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am. J. Pathol. 1993, 142, 557-567.

[14] Jhaveri, M.S.; Rait, A.S.; Chung, K.N.; Trepel, J.B.; Chang, E.H. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol. Cancer Ther. 2004, 3, 1505-1512.

[15] Zhang, Y.; Li, R.J.; Ing, X.; Tian, W.; Yao, H.J.; Men, Y.; You, Y.; Zhang, L.; Ju, R.J.; Wang, X.X.; Zhou, J.; Chen, J.X.; Li, N.; Lu, W.L. Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer. Mol. Pharm. 2011, 8, 162-175.

[16] Li, X.; Ryan, G.R.; Lu, W.L.; Hong, H.Y.; Liang, G.W.; Zhang, Y.T.; Liu, Y.; Long, C.; Ma, X.; Yuan, L.; Wang, J.C.; Zhang, X.; Zhang, Q. A novel stealth liposomal topotecan with amlodipine: apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia. J. Controlled Release. 2006, 112, 186-198.

[17] Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46, 6387-6392.

[18] Robinson, B.D.; Sica, G.L.; Liu, Y.F.; Rohan, T.E.; Gertler, F.B.; Condeelis, J.S.; Jones, J.G. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin. Cancer Res. 2009, 15, 2433-2441.

[19] Wyckoff, J.B.; Wang, Y.; Lin, E.Y.; Li, J.F.; Goswami, S.; Stanley, E.R.; Segall, J.E.; Pollard, J.W.; Condeelis, J. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007, 67, 2649-2656.

叶酸偶联表阿霉素脂质体的构建及其增强侵袭性乳腺癌细胞摄取和核定位效应的研究

Construction of folate-conjugated epirubicin liposomes for enhancing the cellular uptake and the co-localization with nuclei of invasive breast cancer cells

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 14

编辑推荐

Metrics

本文评价

[1]	周楚杭, 胡新平, 刘琦, 王乐淇, 周远航, 靳尧, 刘艳. 增强抗肿瘤药物肿瘤靶向性递送的叶酸修饰的pH敏感聚合物胶束[J]. 中国药学(英文版), 2020, 29(9): 626-636.
[2]	傅洪哲, 宋佳芳, 宋歌, 宋思洋, 樊志璞, 杨岸蒲, 何冰, 代文兵, 张华, 王学清, 张强. Rho GTP激酶对细胞摄取单壁碳纳米角的影响[J]. 中国药学(英文版), 2017, 26(6): 395-403.
[3]	胡英杰, 张婧莹, 刘磊, 阎妍, 沐黎敏, 白婧, 吴佳栓, 吕万良. 环巴胺-磷脂共聚物修饰的功能化表阿霉素脂质体及其在异质性乳腺癌中的体外治疗效应[J]. 中国药学(英文版), 2017, 26(4): 255-264.
[4]	秦蒙蒙, 李轶凡, 何冰, 卫备, 代文兵, 张华, 王学清, 张强. 细胞内蛋白质在金纳米粒表面的吸附影响金纳米粒的细胞摄取和胞内分布[J]. 中国药学(英文版), 2016, 25(9): 651-659.
[5]	邱崇, 崔仕贺, 孙晶, 王坚成. 不同工艺制备的CLD/siRNA纳米粒体外性质差异性研究[J]. 中国药学(英文版), 2016, 25(9): 660-668.
[6]	沐黎敏, 吴佳栓, 谢红军, 刘磊, 曾凡, 阎妍, 赵曜, 胡英杰, 卜英子, 吕万良. 一种新葡萄糖偶联物材料TPGS1000-Glu及其修饰的表阿霉素脂质体在治疗脑胶质瘤中的应用[J]. 中国药学(英文版), 2016, 25(4): 266-274.
[7]	刘磊, 居瑞军, 谢红军, 曾凡, 张诚翔, 赵炜煜, 吕万良. 复方表阿霉素奎宁注射剂对耐药乳腺癌的治疗效应与机制研究[J]. 中国药学(英文版), 2015, 24(9): 563-571.
[8]	赵阳, 任伟, 钟婷, 王超, 张卫强, 黄丹, 张爽, 郭阳, 姚鑫, 张烜, 张强. H7K(R2)2修饰的pH敏感脂质体对U87-MG细胞的靶向作用[J]. 中国药学(英文版), 2015, 24(10): 660-665.
[9]	杨科, 李星火, 李丹, 柯曦宇, 张烜, 张强. c9, t11-CLAPTX与t10, c12-CLA-PTX对MCF-7细胞的体内外抗肿瘤作用[J]. 中国药学(英文版), 2014, 23(11): 751-759.
[10]	李捷思, 杨科, 柯曦宇, 杜若, 张烜*, 张强. CLA-PTX对黑色素瘤B16-F10的体内外抗肿瘤作用[J]. 中国药学(英文版), 2014, 23(1): 46-53.
[11]	张小飞, 崔征, 张孝进, 何冰, 王学清, 张华, 钟振林, 张强^*. 包载香豆素-6的PEO-(hb-PG)-g-PCL杂臂聚合物胶束的体外评价, 细胞摄取以及跨膜转运[J]. , 2013, 22(3): 251-258.
[12]	门萤, 王小星, 居瑞军, 田玮, 应雪, 姚红娟, 张燕, 李若婧, 吕万良^*. 高效液相紫外色谱法同时测定抗耐药脂质体中的表阿霉素、氨氯地平和地喹氯铵[J]. , 2010, 19(4): 300-306.
[13]	刘立婷, 齐宪荣^* . PEG修饰对PEI聚电解质复合物的药学特性及人乳腺癌细胞的摄取效率影响的研究 [J]. , 2008, 17(4): 291-296.
[14]	董梅, 冯奉仪^*, 付强, 朱珠. 高剂量表阿霉素在肿瘤患者中的药物动力学和药效学研究[J]. , 2000, 9(2): 92-95.